Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

Blood

Volumn 105, Issue 12, 2005, Pages 4573-4575

  McLaughlin, Peter ^a   Estey, Elihu ^b   Glassman, Armand ^b   Romaguera, Jorge ^b   Samaniego, Felipe ^b   Ayala, Ana ^b   Hayes, Kimberly ^b   Maddox, Anne Marie ^b   Preti, H Alejandro ^b   Hagemeister, Fredrick B ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CANCER REGRESSION; CANCER STAGING; CANCER THERAPY; CHEMOTHERAPY; CHROMOSOME 7P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; CYTOGENETICS; DNA DAMAGE; DRUG INDUCED DISEASE; FEMALE; HUMAN; LYMPHOMA; MALE; MONOSOMY 7; MYELODYSPLASIA; PRIORITY JOURNAL; RISK FACTOR; SHORT COURSE THERAPY; TREATMENT OUTCOME;

EID: 20444423607     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3035     Document Type: Article

References (25)

1. Pedersen-Bjergaard J, Ersbøll J, Sørensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med. 1985;103:195-200.
2. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17:2454-2460.
3. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14:1262-1268.
4. Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine, mitoxantrone, dexamethasone compared with an alternating triple therapy regimen in patients with stage IV indolent lymphoma. Blood. 2002;100:4351-4357.
5. Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as frontline treatment for patients with follicular lymphoma. J Clin Oncol. 2004;22:2654-2661.
6. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000;27(suppl 12):37-41.
7. McLaughlin P, Rodriguez MA, Hagemeister FB, et al. Stage IV indolent lymphoma: a randomized study of concurrent vs sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab monoclonal antibody therapy, with interferon maintenance [abstract]. Proc ASCO. 2003;22:564.
8. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999;93:3081-3087.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100: 2292-2302.
10. Mitelman F, ed. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
11. Kaplan FL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Kampmeier P, Spielberger R, Dickstein J, et al. Increased incidence of second neoplasms in patients treated with interferon α 2b for hairy cell leukemia: a clinicopathologic assessment. Blood. 1994;83:2931-2938.
13. Orchard JA, Bolam S, Oscier DG. Association of myelodysplastic changes with purine analogues. Br J Haematol. 1998;100:677-679.
14. Kroft SH, Tallman MS, Shaw JM, Thangavelu M, Peterson LC. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2CdA) [letter]. Leukemia. 1997;11:170.
15. Todd SA, Morris TCM, Alexander HD. Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin. Leuk Lymphoma. 2002;43:1343-1344.
16. Abe M, Tanaka Y, Shinohara M, et al. Myelodysplastic syndrome/acute myelogenous leukaemia related to adjuvant chemotherapy with oral pyrimidine anti-metabolites. Br J Haematol. 2000;111: 711-715.
17. Saso R, Kulkarni S, Mitchell P, et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer. 2000;83:91-94.
18. André M, Meunier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103:1222-1228.
19. Pedersen-Bjergaard J, Pedersen M, Myhre J, Geisler C. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia. 1997;11:1654-1660.
20. Streubel B, Sauerland C, Heil G, et al. Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12. Br J Haematol. 1998;100:521-533.
21. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569-577.
22. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Can Res. 2001;7:3580-3589.
23. Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an Intergroup Study, Cancer and Leukemia Group B 9011. J Clin Oncol. 2002;20:3878-3884.
24. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186.
25. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906.